Parliamentary panel recommends bringing of CDSCO under Dept of Pharmaceuticals
Parliamentary panel attached to the Ministry of Chemicals and Fertilisers has asked the Ministry to check on quality of drugs.
Parliamentary panel attached to the Ministry of Chemicals and Fertilisers has asked the Ministry to take up urgently the matter of bringing the Central Drugs Standard Control Organisation (CDSCO) under the administrative purview of the Department of Pharmaceuticals for better check on quality of drugs.
Bringing back the contentious issue into focus, the standing committee headed by Gopinath Munde said the monitoring the quality of drugs and check on spurious drugs are interlinked with pricing and availability of drugs.
“The Department of Pharmaceuticals (DoP) may not be able to do full justice to its role regarding pricing and availability of drugs if the quality control set up does not come within its purview. The Committee, therefore, desire that the DoP should take up the matter regarding bringing the quality control and regulatory mechanism under one umbrella i.e. the DoP,” according to a recent report.
The debate has been going on for some time now over the issue. The DoP itself had taken up the matter with the Cabinet secretariat and the Prime Minister’s Office, clearly stating that the CDSCO may be brought under the DoP.
Pushing the matter to the PMO, Lok Sabha member Dr Sujan Chakraborty had also written to the Prime Minister some time back with the same demand. He pointed out that the very creation of the DoP was to bring all important functions under the single Department to facilitate growth of pharma industry. If the CDSCO was not brought under DoP, the very purpose of the DoP would remain unfulfilled, he said.
The DoP, in its submission to the PMO, also claimed that as the issues relating to pricing, availability and quality of medicines are closely interlinked, CDSCO should be a part of the DoP so that it may be able to play its role more effectively to achieve its main objective to ensure availability of life saving drugs at, reasonable prices as envisaged in the drug policy.
“Quality is an essential parameter while considering the pricing and availability of medicines. In the absence of jurisdiction over the issue of quality of medicines, the DoP finds itself handicapped to do full justice to the role assigned to it. It is, therefore, extremely important to bring the quality control set up under the DoP,” the department conveyed to the PMO.
“Since the function of price control and the administrative control of National Pharmaceutical Pricing Authority (NPPA) is already vested with the Department, this Department would be well equipped to address the significant issues related to the Pharmaceuticals,” it said.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance